Patterson Companies Reports Fiscal 2025 Third Quarter Operating Results

Rhea-AI Summary

Patterson Companies (PDCO) reported fiscal 2025 third quarter results with net sales declining 2.7% to $1.57 billion. The company posted GAAP earnings of $0.35 per diluted share and adjusted earnings of $0.43 per diluted share, both impacted by a cybersecurity attack on Change Healthcare.

Key financial highlights include:

• Net income decreased to $31.3 million from $47.7 million year-over-year
• Dental segment sales reached $596.3 million with internal sales declining 6.0%
• Animal Health segment reported sales of $972.4 million with internal sales up 0.2%

The company is in the process of being acquired by Patient Square Capital for $31.35 per share in an all-cash transaction valued at approximately $4.1 billion. The deal is expected to close in April 2025, after which Patterson will become private. Through the first nine months of fiscal 2025, Patterson returned $119.2 million to shareholders through dividends and share repurchases.

Positive

• Animal Health segment showed resilience with 0.2% internal sales growth
• Value-added services in Animal Health increased 10.8%
• Returned $119.2M to shareholders through dividends and buybacks
• Secured acquisition deal at $31.35 per share, providing immediate shareholder value

Negative

• Overall net sales declined 2.7% to $1.57 billion
• Net income dropped to $31.3M from $47.7M year-over-year
• Dental segment internal sales decreased 6.0%
• Dental consumables sales declined 6.2%
• Equipment sales decreased 6.9% in Dental segment
• Free cash flow declined by $49.6M compared to first nine months of FY2024

Insights

Financial Analyst

Patterson Companies' Q3 FY2025 results reveal significant operational challenges as the company approaches its $4.1 billion acquisition by Patient Square Capital. Net sales decreased 2.7% to $1.57 billion, with GAAP EPS falling to $0.35 from $0.52 year-over-year. The 32.7% profit decline reflects both market headwinds and specific operational challenges.

The dental segment shows concerning weakness with internal sales dropping 6.0% across all categories - consumables (-6.2%), equipment (-6.9%), and value-added services (-2.4%). This performance signals potential structural issues beyond cyclical factors, particularly as the cybersecurity attack on Change Healthcare continues to disrupt the value-added services business. The animal health segment barely maintained stability with a minimal 0.2% internal sales increase.

Cash flow metrics are particularly troubling, with the company using $3.9 million in cash from operations (after collecting deferred receivables) compared to generating $50.5 million in the prior-year period. This 107.7% deterioration in operational cash generation deserves investor attention, especially as Patterson maintained its $0.26 quarterly dividend and continued share repurchases.

The narrow spread between the current share price ($31.07) and acquisition offer ($31.35) indicates market confidence in the April 2025 closing timeline, despite these operational challenges. For Patient Square Capital, these results may validate their privatization strategy, providing opportunity to address operational inefficiencies and market challenges without quarterly public scrutiny.

• Third quarter reported net sales decreased 2.7 percent year-over-year to $1.57 billion, and internal sales decreased 2.4 percent.
• Delivered third quarter GAAP earnings of $0.35 per diluted share and adjusted earnings¹ of $0.43 per diluted share; both GAAP and adjusted earnings¹ were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year.
• Returned $119.2 million to shareholders in the form of cash dividends and share repurchases through the first nine months of fiscal 2025.

ST. PAUL, Minn.--(BUSINESS WIRE)-- Patterson Companies, Inc. (Nasdaq: PDCO) today reported operating results for its fiscal 2025 third quarter ended January 25, 2025.

“As we continue to progress toward closing our transaction with Patient Square Capital, our team remains focused on executing our strategy,” said Don Zurbay, President and CEO of Patterson Companies. “While our third quarter results were impacted by challenging market conditions, we remain confident in the long-term strength of Patterson’s value proposition as an indispensable partner to customers across the durable and attractive dental and animal health end markets.”

Pending Transaction

As announced on December 11, 2024, Patterson entered into a definitive agreement under which Patient Square Capital, a dedicated health care investment firm, has agreed to acquire Patterson for $31.35 per share in an all-cash transaction valued at approximately $4.1 billion, including the refinancing of Patterson’s receivables facilities. The transaction is expected to close in April 2025, subject to the satisfaction of customary closing conditions, including approval by Patterson’s shareholders. Upon completion of the transaction, Patterson will become a privately held company, and its common stock will no longer be traded on the NASDAQ Global Select Market (Nasdaq).

Third Quarter Fiscal 2025 Results

Consolidated net sales were $1.57 billion (see attached Sales Summary for further details), a decrease of 2.7 percent compared to the same period last year. Internal sales, which are adjusted for the effects of currency translation, the net impact of an interest rate swap and contributions from recent acquisitions, decreased 2.4 percent over the prior year period.

Reported net income attributable to Patterson Companies, Inc. for the third quarter of fiscal 2025 was $31.3 million, or $0.35 per diluted share, compared to $47.7 million, or $0.52 per diluted share, in the third quarter of fiscal 2024. Adjusted net income¹ attributable to Patterson Companies, Inc., which excludes deal amortization, totaled $38.7 million for the third quarter of fiscal 2025, or $0.43 per diluted share, compared to $55.0 million, or $0.59 per diluted share, in the third quarter of fiscal 2024. Reported and adjusted net income attributable to Patterson Companies, Inc. was negatively impacted in the fiscal third quarter by a pre-tax year-over-year increase in LIFO expense of $7.4 million, a $2.4 million pre-tax year-over-year increase in legal expenses and a $4.0 million pre-tax increase in employee benefit expense due to medical claims compared to the prior year period. In addition, the year-over-year decrease in reported and adjusted net income attributable to Patterson Companies, Inc. in the third quarter of fiscal 2025 was also related to lower sales of dental consumables and equipment and the continued negative impact of the widely reported cybersecurity attack on vendor Change Healthcare, within the value-added services category of the dental segment.

Patterson Dental

Reported net sales in the Dental segment for the third quarter of fiscal 2025 were $596.3 million. Internal sales decreased 6.0 percent compared to the fiscal 2024 third quarter. Internal sales of consumables decreased 6.2 percent year-over-year. Compared to the prior year period, internal sales of equipment decreased 6.9 percent. Internal sales of value-added services decreased 2.4 percent compared to the prior year period, primarily due to the negative impact of the cybersecurity attack on Change Healthcare.

Patterson Animal Health

Reported net sales in the Animal Health segment for the third quarter of fiscal 2025 were $972.4 million. Internal sales increased 0.2 percent compared to the fiscal 2024 third quarter. Compared to the prior year period, internal sales of consumables were flat, equipment decreased 1.1 percent and value-added services increased 10.8 percent.

Balance Sheet and Capital Allocation

During the first nine months of fiscal 2025, Patterson Companies used $735.1 million of cash from operating activities and collected deferred purchase price receivables of $731.1 million, using $3.9 million in cash, compared to generating $50.5 million during the first nine months of fiscal 2024. Free cash flow¹ (see definition below and attached free cash flow table) during the first nine months of fiscal 2025 declined by $49.6 million compared to the first nine months of fiscal 2024.

In the third quarter of fiscal 2025, Patterson Companies paid a quarterly cash dividend of $0.26 per share, returning $22.9 million to shareholders. During the first nine months of fiscal 2025, Patterson Companies returned $119.2 million to shareholders in the form of cash dividends and share repurchases.

Year-to-Date Results

Consolidated reported net sales for the first nine months of fiscal 2025 totaled $4.79 billion, a 1.2 percent year-over-year decrease. Internal sales for the first nine months of fiscal 2025, which are adjusted for the effects of currency translation and the net impact of an interest rate swap and contributions from recent acquisitions, decreased 1.5 percent year-over-year. Through the first nine months of fiscal 2025, Dental segment internal sales decreased 3.8 percent, including a 2.5 percent decrease in consumables, a 6.0 percent decline in equipment and a 4.0 percent decrease in value-added services. Through the first nine months of fiscal 2025, Animal Health segment internal sales decreased 0.2 percent, including 0.5 percent decrease in consumables, a 1.1 percent decline in equipment and a 12.2 percent increase in value-added services.

Reported net income attributable to Patterson Companies, Inc. was $71.7 million, or $0.81 per diluted share, compared to $118.9 million, or $1.26 per diluted share in last year's period. Adjusted net income¹ attributable to Patterson Companies, Inc., which excludes deal amortization, integration and business restructuring expenses, an inventory pre-payment write-off and a gain on the sale of an investment totaled $101.6 million, or $1.14 per diluted share, compared to $140.9 million, or $1.49 per diluted share, in the year-ago period.

Financial Guidance and Conference Call

In light of the Company’s previously announced agreement to be acquired by Patient Square Capital, Patterson will not be providing an update to forward-looking earnings guidance and will not conduct a quarterly earnings call nor publish supplemental earnings materials with the financial community that discusses fiscal 2025 third quarter results.

¹Non-GAAP Financial Measures

The term “internal sales” used in this release represents net sales adjusted for the effects of currency translation, the net impact of an interest rate swap and contributions from recent acquisitions. Foreign currency impact represents the difference in results that is attributable to fluctuations in currency exchange rates the company uses to convert results for all foreign entities where the functional currency is not the U.S. dollar. The company calculates the impact as the difference between the current period results translated using the current period currency exchange rates and using the comparable prior period’s currency exchange rates. The company believes the disclosure of net sales excluding the impact of foreign currency and an interest rate swap provides useful supplementary information to investors in light of fluctuations in these variables that are independent of our period-over-period performance.

The term “free cash flow” used in this release is defined as net cash used in operating activities less capital expenditures plus the collection of deferred purchase price receivables.

The Reconciliation of GAAP to non-GAAP Measures table appearing behind the accompanying financial information is provided to adjust reported GAAP measures, namely net sales, gross profit, operating expenses, operating income, other income (expense), net, income before taxes, income tax expense, net income, net loss attributable to noncontrolling interests, net income attributable to Patterson Companies, Inc., and diluted earnings per share attributable to Patterson Companies, Inc. for the impact of deal amortization, integration and business restructuring expenses, an interest rate swap, an inventory pre-payment write-off, and a gain on the sale of an investment along with any related tax effects of these items.

• Deal amortization represents non-cash intangible amortization expense, primarily related to the acquisition of Animal Health International.

• Integration and business restructuring expenses represent restructuring charges to better align our organization to current market opportunities.

• Interest rate swap -- Our customer financing net sales includes the impact of changes in interest rates on deferred purchase price receivables, as the average interest rate in our contract portfolio may not fluctuate at the same rate as interest rate markets, resulting in an increase or reduction of gain on contract sales.
  
  We enter into an interest rate swap to hedge a portion of the related interest rate risk. These agreements do not qualify for hedge accounting, and the gains or losses on an interest rate swap are reported in other income and expense in our condensed consolidated statements of operation and other comprehensive income.
  
  We present a non-GAAP adjustment to reclassify the mark-to-market adjustment on the interest rate swap from other income (expense) to net sales to align the swap impact with the impact on customer financing net sales. We believe adjusted net sales, adjusted gross profit and adjusted operating income, which include the gains and losses on the interest rate swap, provide additional comparability from period to period because they present the impact of interest rate fluctuations, net of the mark-to-market swap adjustment, within adjusted net sales. We note the net impact of interest rate fluctuations has a minimal impact on net income.

• Inventory pre-payment write-off represents the write-off of the remaining balance of a transaction initiated during the COVID-19 pandemic. The inventory prepayment was made in a period of supply chain disruptions and increased demand for PPE and does not represent our normal process for purchasing inventory. The remaining balance of the prepayment was determined to be uncollectible in the second quarter of fiscal 2025.

• Gain on investment relates to the sale of our investment in VetSource.

Management believes that these non-GAAP measures may provide a helpful representation of the company’s performance and enable comparison of financial results between periods where certain items may vary independent of business performance. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

About Patterson Companies Inc.

Patterson Companies Inc. (Nasdaq: PDCO) connects dental and animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. Our comprehensive portfolio, distribution network and supply chain is equaled only by our dedicated, knowledgeable people who deliver unrivalled expertise and unmatched customer service and support.

Learn more: pattersoncompanies.com

Forward-Looking Statements

This press release contains statements that are forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include information concerning the proposed merger and the ability to consummate the proposed merger, our liquidity and our possible or assumed future results of operations, including descriptions of our business strategies. These statements often include words such as “believe,” “expect,” “project,” “potential,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “would,” “should,” “could,” “forecasts” or similar words

These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. We believe these assumptions are reasonable, but you should understand that these statements are not guarantees of performance or results, and our actual results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent releases or reports.

These statements involve risks, estimates, assumptions, and uncertainties that could cause actual results to differ materially from those expressed in these statements and elsewhere in this release. These uncertainties include, but are not limited to, the inability to consummate the merger within the anticipated time period, or at all, due to any reason, including the failure to obtain required regulatory and shareholder approvals, satisfy the other conditions to the consummation of the merger or complete necessary financing arrangements; the risk that the merger disrupts our current plans and operations or diverts management’s attention from its ongoing business; the effects of the merger on our business, operating results, and ability to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom we do business; the risk that our stock price may decline significantly if the merger is not consummated; the nature, cost and outcome of any legal proceedings related to the merger; our dependence on suppliers to manufacture and supply substantially all of the products we sell; potential disruption of distribution capabilities, including service issues with third-party shippers; our dependence on relationships with sales representatives and service technicians to retain customers and develop business; risks of selling private label products, including the risk of adversely affecting our relationships with suppliers; adverse changes in supplier rebates or other purchasing incentives; the risk of technological and market obsolescence for the products we sell; the risk of failing to innovate and develop new and enhanced software and e-services products; our dependence on positive perceptions of Patterson’s reputation; risks associated with illicit human use of pharmaceutical products we distribute; risks inherent in acquiring and disposing of assets or other businesses and risks inherent in integrating acquired businesses; turnover or loss of key personnel or highly skilled employees; risks associated with information systems, software products and cyber-security attacks; risks inherent in our growing use of artificial intelligence systems to automate processes and analyze data; adverse impacts of wide-spread public health concerns as we experienced with the COVID-19 pandemic and may experience in the future; risks related to climate change; our ability to comply with restrictive covenants and other limits in our credit agreement; the risk that our governing documents and Minnesota law may discourage takeovers and business combinations; the effects of the highly competitive dental and animal health supply markets in which we compete; the effects of consolidation within the dental and animal health supply markets; risks from the formation or expansion of GPOs, provider networks and buying groups that may place us at a competitive disadvantage; exposure to the risks of the animal production business, including changing consumer demand, the cyclical livestock market, weather conditions, the availability of natural resources and other factors outside our control, and the risks of the companion animal business, including the possibility of disease adversely affecting the pet population; exposure to the risks of the health care industry, including changes in demand due to political, economic and regulatory influences and other factors outside our control; increases in over-the-counter sales and e-commerce options; risks of litigation and government inquiries and investigations, including the diversion of management’s attention, the cost of defending against such actions, the possibility of damage awards or settlements, fines or penalties, or equitable remedies (including but not limited to the revocation of or non-renewal of licenses) and inherent uncertainty; failure to comply with health care fraud or other laws and regulations; change and uncertainty in the health care industry; failure to comply with existing or future U.S. or foreign laws and regulations including those governing the distribution of pharmaceuticals and controlled substances; failure to comply with evolving data privacy laws and regulations; tax legislation; risks inherent in international operations, including currency fluctuations; and uncertain macro-economic conditions, including inflationary pressures.

The foregoing review of important factors that could cause actual results to differ from expectations should not be construed as exhaustive and should be read in conjunction with the information contained or incorporated by reference in our Annual Report on Form 10-K for the year ended April 27, 2024 filed with the SEC on June 18, 2024 and our definitive proxy statement for our 2024 annual meeting of shareholders filed with the SEC on August 2, 2024 and our recent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

The information contained in this release is made only as of the date hereof, even if subsequently made available on our website or otherwise.

PATTERSON COMPANIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
	Three Months Ended								Nine Months Ended
	January 25, 2025				January 27, 2024				January 25, 2025				January 27, 2024
Net sales	$	1,572,411			$	1,616,095			$	4,788,528			$	4,845,612
Gross profit		320,824				351,006				961,525				1,009,087
Operating expenses		275,383				280,994				849,079				843,950
Operating income		45,441				70,012				112,446				165,137
Other income (expense):
Other income, net		8,147				3,653				19,566				22,650
Interest expense		(10,753	)			(11,725	)			(35,774	)			(31,879	)
Income before taxes		42,835				61,940				96,238				155,908
Income tax expense		11,665				14,347				24,733				37,330
Net income		31,170				47,593				71,505				118,578
Net loss attributable to noncontrolling interests		(85	)			(110	)			(234	)			(317	)
Net income attributable to Patterson Companies, Inc.	$	31,255			$	47,703			$	71,739			$	118,895
Earnings per share attributable to Patterson Companies, Inc.:
Basic	$	0.35			$	0.52			$	0.81			$	1.26
Diluted	$	0.35			$	0.52			$	0.81			$	1.26
Weighted average shares:
Basic		88,306				92,009				88,197				94,088
Diluted		89,070				92,519				88,871				94,704
Dividends declared per common share	$	—			$	0.26			$	0.52			$	0.78

PATTERSON COMPANIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
	January 25, 2025			April 27, 2024
ASSETS
Current assets:
Cash and cash equivalents	$	134,996		$	114,462
Receivables, net		469,924			547,287
Inventory, net		889,348			782,898
Prepaid expenses and other current assets		343,366			334,116
Total current assets		1,837,634			1,778,763
Property and equipment, net		227,802			229,081
Operating lease right-of-use assets, net		121,613			122,295
Goodwill and identifiable intangibles, net		330,145			349,589
Investments		88,649			166,320
Long-term receivables, net and other		226,743			250,684
Total assets	$	2,832,586		$	2,896,732
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	644,861		$	745,375
Other accrued liabilities		204,740			245,610
Operating lease liabilities		26,945			32,815
Current maturities of long-term debt		126,875			122,750
Borrowings on revolving credit		302,000			186,000
Total current liabilities		1,305,421			1,332,550
Long-term debt		321,763			328,911
Non-current operating lease liabilities		98,053			92,464
Other non-current liabilities		117,434			141,075
Total liabilities		1,842,671			1,895,000
Stockholders' equity		989,915			1,001,732
Total liabilities and stockholders' equity	$	2,832,586		$	2,896,732

PATTERSON COMPANIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
	Nine Months Ended
	January 25, 2025				January 27, 2024
Operating activities:
Net income	$	71,505			$	118,578
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization		68,784				65,198
Stock-based compensation		16,568				15,395
Non-cash (gains) losses and other, net		(9,695	)			4,120
Change in assets and liabilities:
Receivables		(615,136	)			(744,275	)
Inventory		(107,461	)			(106,328	)
Accounts payable		(101,856	)			(43,533	)
Accrued liabilities		(16,348	)			(14,510	)
Other changes from operating activities, net		(41,429	)			(14,494	)
Net cash used in operating activities		(735,068	)			(719,849	)
Investing activities:
Additions to property and equipment and software		(46,427	)			(51,196	)
Collection of deferred purchase price receivables		731,146				770,319
Payments related to acquisitions, net of cash acquired		(11,967	)			(1,108	)
Sale of investment		86,408				—
Net cash provided by investing activities		759,160				718,015
Financing activities:
Dividends paid		(69,165	)			(75,021	)
Repurchases of common stock		(50,000	)			(214,587	)
Payments on long-term debt		(3,375	)			(35,250	)
Draw on revolving credit		116,000				286,000
Other financing activities		3,505				4,767
Net cash used in financing activities		(3,035	)			(34,091	)
Effect of exchange rate changes on cash		(523	)			254
Net change in cash and cash equivalents		20,534				(35,671	)
Cash and cash equivalents at beginning of period		114,462				159,669
Cash and cash equivalents at end of period	$	134,996			$	123,998

PATTERSON COMPANIES, INC.
SALES SUMMARY
(Dollars in thousands)
(Unaudited)
	January 25, 2025			January 27, 2024			Total Sales Growth			Foreign Exchange Impact			Net Interest Rate Swap			Acquisition Impact			Internal Sales Growth
Three Months Ended
Consolidated net sales
Consumable	$	1,242,015		$	1,262,290		(1.6	)%		(0.2	)%		—	%		0.3	%		(1.7	)%
Equipment		229,432			245,262		(6.5	)		(0.4	)		—			—			(6.1	)
Value-added services and other		100,964			108,543		(7.0	)		(0.1	)		(5.3	)		—			(1.6	)
Total	$	1,572,411		$	1,616,095		(2.7	)%		(0.2	)%		(0.3	)%		0.2	%		(2.4	)%
Dental
Consumable	$	327,637		$	350,953		(6.6	)%		(0.4	)%		—	%		—	%		(6.2	)%
Equipment		195,897			211,352		(7.3	)		(0.4	)		—			—			(6.9	)
Value-added services and other		72,794			74,832		(2.7	)		(0.3	)		—			—			(2.4	)
Total	$	596,328		$	637,137		(6.4	)%		(0.4	)%		—	%		—	%		(6.0	)%
Animal Health
Consumable	$	914,378		$	911,337		0.3	%		(0.1	)%		—	%		0.4	%		—	%
Equipment		33,535			33,910		(1.1	)		—			—			—			(1.1	)
Value-added services and other		24,467			22,030		11.1			0.2			—			0.1			10.8
Total	$	972,380		$	967,277		0.5	%		(0.1	)%		—	%		0.4	%		0.2	%
Corporate
Value-added services and other	$	3,703		$	11,681		n/m			—	%		n/m			—	%		(26.9	)%
Total	$	3,703		$	11,681		n/m			—	%		n/m			—	%		(26.9	)%

PATTERSON COMPANIES, INC.
SALES SUMMARY
(Dollars in thousands)
(Unaudited)
	January 25, 2025			January 27, 2024			Total Sales Growth			Foreign Exchange Impact			Net Interest Rate Swap			Acquisition Impact			Internal Sales Growth
Nine Months Ended
Consolidated net sales
Consumable	$	3,867,636		$	3,897,378		(0.8	)%		0.1	%		—	%		0.1	%		(1.0	)%
Equipment		604,453			639,526		(5.5	)		(0.2	)		—			—			(5.3	)
Value-added services and other		316,439			308,708		2.5			0.1			2.6			—			(0.2	)
Total	$	4,788,528		$	4,845,612		(1.2	)%		0.1	%		0.1	%		0.1	%		(1.5	)%
Dental
Consumable	$	1,020,662		$	1,049,492		(2.7	)%		(0.2	)%		—	%		—	%		(2.5	)%
Equipment		514,908			549,028		(6.2	)		(0.2	)		—			—			(6.0	)
Value-added services and other		222,797			232,298		(4.1	)		(0.1	)		—			—			(4.0	)
Total	$	1,758,367		$	1,830,818		(4.0	)%		(0.2	)%		—	%		—	%		(3.8	)%
Animal Health
Consumable	$	2,846,974		$	2,847,886		—	%		0.3	%		—	%		0.2	%		(0.5	)%
Equipment		89,545			90,498		(1.1	)		—			—			—			(1.1	)
Value-added services and other		72,862			64,505		13.0			0.8			—			—			12.2
Total	$	3,009,381		$	3,002,889		0.2	%		0.3	%		—	%		0.1	%		(0.2	)%
Corporate
Value-added services and other	$	20,780		$	11,905		n/m			—	%		n/m			—	%		3.4	%
Total	$	20,780		$	11,905		n/m			—	%		n/m			—	%		3.4	%

PATTERSON COMPANIES, INC.
OPERATING INCOME BY SEGMENT
(In thousands)
(Unaudited)
	Three Months Ended								Nine Months Ended
	January 25, 2025				January 27, 2024				January 25, 2025				January 27, 2024
Operating income (loss)
Dental	$	42,079			$	53,630			$	102,797			$	147,577
Animal Health		31,976				32,104				86,964				88,143
Corporate		(28,614	)			(15,722	)			(77,315	)			(70,583	)
Total	$	45,441			$	70,012			$	112,446			$	165,137

PATTERSON COMPANIES, INC.
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
(Dollars in thousands, except per share amounts)
(Unaudited)
For the three months ended January 25, 2025		GAAP				Deal amortization				Integration and business restructuring expenses			Interest rate swap				Inventory pre- payment write-off			Gain on investment			Non-GAAP
Net sales		$	1,572,411			$	—			$	—		$	2,298			$	—		$	—		$	1,574,709
Gross profit			320,824				—				—			2,298				—			—			323,122
Operating expenses			275,383				(9,723	)			—			—				—			—			265,660
Operating income			45,441				9,723				—			2,298				—			—			57,462
Other income (expense), net			(2,606	)			—				—			(2,298	)			—			—			(4,904	)
Income before taxes			42,835				9,723				—			—				—			—			52,558
Income tax expense			11,665				2,305				—			—				—			—			13,970
Net income			31,170				7,418				—			—				—			—			38,588
Net loss attributable to noncontrolling interests			(85	)			—				—			—				—			—			(85	)
Net income attributable to Patterson Companies, Inc.		$	31,255			$	7,418			$	—		$	—			$	—		$	—		$	38,673
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.35			$	0.08			$	—		$	—			$	—		$	—		$	0.43
Gross margin			20.4	%																				20.5	%
Operating margin			2.9	%																				3.6	%
Effective tax rate			27.2	%																				26.6	%
For the three months ended January 27, 2024		GAAP				Deal amortization				Integration and business restructuring expenses			Interest rate swap				Inventory pre- payment write-off			Gain on investment			Non-GAAP
Net sales		$	1,616,095			$	—			$	—		$	(3,474	)		$	—		$	—		$	1,612,621
Gross profit			351,006				—				—			(3,474	)			—			—			347,532
Operating expenses			280,994				(9,630	)			—			—				—			—			271,364
Operating income			70,012				9,630				—			(3,474	)			—			—			76,168
Other income (expense), net			(8,072	)			—				—			3,474				—			—			(4,598	)
Income before taxes			61,940				9,630				—			—				—			—			71,570
Income tax expense			14,347				2,304				—			—				—			—			16,651
Net income			47,593				7,326				—			—				—			—			54,919
Net loss attributable to noncontrolling interests			(110	)			—				—			—				—			—			(110	)
Net income attributable to Patterson Companies, Inc.		$	47,703			$	7,326			$	—		$	—			$	—		$	—		$	55,029
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.52			$	0.08			$	—		$	—			$	—		$	—		$	0.59
Gross margin			21.7	%																				21.6	%
Operating margin			4.3	%																				4.7	%
Effective tax rate			23.2	%																				23.3	%
* May not sum due to rounding

PATTERSON COMPANIES, INC.
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
(Dollars in thousands, except per share amounts)
(Unaudited)
For the nine months ended January 25, 2025		GAAP				Deal amortization				Integration and business restructuring expenses				Interest rate swap				Inventory pre- payment write-off				Gain on investment				Non-GAAP
Net sales		$	4,788,528			$	—			$	—			$	(2,181	)		$	—			$	—			$	4,786,347
Gross profit			961,525				—				6,947				(2,181	)			—				—				966,291
Operating expenses			849,079				(29,091	)			(3,262	)			—				(3,797	)			—				812,929
Operating income			112,446				29,091				10,209				(2,181	)			3,797				—				153,362
Other income (expense), net			(16,208	)			—				—				2,181				—				(3,803	)			(17,830	)
Income before taxes			96,238				29,091				10,209				—				3,797				(3,803	)			135,532
Income tax expense			24,733				6,914				2,571				—				949				(951	)			34,216
Net income			71,505				22,177				7,638				—				2,848				(2,852	)			101,316
Net loss attributable to noncontrolling interests			(234	)			—				—				—				—				—				(234	)
Net income attributable to Patterson Companies, Inc.		$	71,739			$	22,177			$	7,638			$	—			$	2,848			$	(2,852	)		$	101,550
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.81			$	0.25			$	0.09			$	—			$	0.03			$	(0.03	)		$	1.14
Gross margin			20.1	%																							20.2	%
Operating margin			2.3	%																							3.2	%
Effective tax rate			25.7	%																							25.2	%
For the nine months ended January 27, 2024		GAAP				Deal amortization				Integration and business restructuring expenses				Interest rate swap				Inventory pre- payment write-off				Gain on investment				Non-GAAP
Net sales		$	4,845,612			$	—			$	—			$	6,087			$	—			$	—			$	4,851,699
Gross profit			1,009,087				—				—				6,087				—				—				1,015,174
Operating expenses			843,950				(28,884	)			—				—				—				—				815,066
Operating income			165,137				28,884				—				6,087				—				—				200,108
Other income (expense), net			(9,229	)			—				—				(6,087	)			—				—				(15,316	)
Income before taxes			155,908				28,884				—				—				—				—				184,792
Income tax expense			37,330				6,913				—				—				—				—				44,243
Net income			118,578				21,971				—				—				—				—				140,549
Net loss attributable to noncontrolling interests			(317	)			—				—				—				—				—				(317	)
Net income attributable to Patterson Companies, Inc.		$	118,895			$	21,971			$	—			$	—			$	—			$	—			$	140,866
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	1.26			$	0.23			$	—			$	—			$	—			$	—			$	1.49
Gross margin			20.8	%																							20.9	%
Operating margin			3.4	%																							4.1	%
Effective tax rate			23.9	%																							23.9	%
* May not sum due to rounding

PATTERSON COMPANIES, INC.
FREE CASH FLOW
(In thousands)
(Unaudited)
	Nine Months Ended
	January 25, 2025				January 27, 2024
Net cash used in operating activities	$	(735,068	)		$	(719,849	)
Additions to property and equipment and software		(46,427	)			(51,196	)
Collection of deferred purchase price receivables		731,146				770,319
Free cash flow	$	(50,349	)		$	(726	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250226788391/en/

INVESTOR: John M. Wright, Investor Relations

TEL: 651.686.1364

EMAIL: investor.relations@pattersoncompanies.com

MEDIA: Patterson Corporate Communications

TEL: 651.905.3349

EMAIL: corporate.communications@pattersoncompanies.com

WEB: pattersoncompanies.com

Source: Patterson Companies, Inc.

FAQ

What is the purchase price for Patterson Companies (PDCO) in the Patient Square Capital acquisition?

Patient Square Capital is acquiring PDCO for $31.35 per share in an all-cash transaction valued at approximately $4.1 billion.

How much did Patterson Companies' (PDCO) revenue decline in Q3 2025?

PDCO's net sales decreased 2.7% year-over-year to $1.57 billion in Q3 2025.

What was Patterson Companies' (PDCO) earnings per share in Q3 2025?

PDCO reported GAAP earnings of $0.35 per share and adjusted earnings of $0.43 per share in Q3 2025.

How much cash did Patterson Companies (PDCO) return to shareholders in the first nine months of fiscal 2025?

PDCO returned $119.2 million to shareholders through cash dividends and share repurchases.

When is the Patterson Companies (PDCO) acquisition expected to close?

The acquisition by Patient Square Capital is expected to close in April 2025.